How much do we know about adherence to biometric monitoring technologies (BioMeTs) in clinical trials?

What did they find? As a result, the authors recommended that sensor-based, non-surrogate, quantitative adherence data should be reported for all BioMeTs. What does that mean in practice?Why does that matter?In short: the more precise your definitions are, the more your data will be able to tell you. Who did this study? Want to learn more?